Skip to main content

Table 1 Demographic and clinical data

From: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients

Variable

Total

Critically morbidly obese

Noncritically obese

Critically nonobese

Dose (mg)

 

100

150

100

150

100

n

31

7

4

7

3

10

Age (years), median (range)

58 (27–85)

45 (27–73)

53.5 (44–63)

58 (48–85)

58 (43–73)

72 (43–85)

% Females

71.0

100

50.0

85.7

100

40

BMIa (kg/m2), median (range)

34.7 (19.6–60.0)

44.2 (40.3–51.7)

52.8 (47.4–60.0)

27.7 (25.2–34.7)

35.5 (34.7–52.4)

23.1 (19.6–38.5)

Weight (kg), median (range)

95 (44–193)

113 (95–121)

157.5 (142–170)

84.1 (62–105)

105 (105–193)

65 (44.0–92.5)

Creatinine (mg/dl), median (range)

1.0 (0.4–3.9)

0.7 (0.6–1.5)

1.3 (0.6–1.7)

1.1 (0.7–1.4)

0.8 (0.7–1.5)

1.0 (0.4–3.0)

CrCla (ml/min/1.73m2)

93.4 ± 51.4

133.1 ± 44.9

112.5 ± 53.2

62.7 ± 38.4

105.4 ± 63.9

75.9 ± 46.1

Albumin (g/dl), median (range)

3 (1.2–4.0)

2.7 (1.9–3.5)

3.1 (2.4–4)

3.5 (2.6–3.9)

3.6 (3.4–3.7)

2.5 (1.2–3.3)

Candida score, median (range)

3 (2–4)b

3 (2–4)

3.5 (3–4)

DTc

DTd

3 (2–4)

SOFAa score, median (range)

6 (0–12)

6 (2–8)

7 (5–10)

5 (2–10)

6 (5–7)

4.5 (0–12)

SAPSa II, median (range)

34 (9–57)

40 (8–57)

34.5 (25–45)

47 (9–53)

41 (18–44)

26 (11–42)

  1. Data are expressed as mean ± standard deviation, except where stated
  2. aBMI, Body mass index; CrCl, creatinine clearance; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment
  3. b For 21 patients
  4. c Directed treatment (DT): three candidemia, three osteoarticular infections, and one urinary tract infection
  5. d DT: one peritonitis, one urinary tract infection, and one osteoarticular infection